Ravidasvir

Ravidasvir is an investigational Discovery and [development of NS5A inhibitors|NS5A inhibitor] in clinical trials for chronic hepatitis C genotype 4.
It is on the WHO Model [List of Essential Medicines|World Health Organization's List of Essential Medicines].
On December 11, 2024 it was approved in Russia under the trade name Konesko for the treatment of chronic hepatitis C in adult patients. In the pivotal clinical trial STORM-C-1, the majority of patients were infected with HCV genotypes 1 or 3. Data from this study in patients with HCV genotypes 2 and 6 are limited, and data on patients with genotypes 4 or 5 are not available.
Preliminary clinical trial results were announced in Nov 2015. In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt. It has been granted conditional registration by the National Pharmaceutical Regulatory Agency of Malaysia.